Serum TAM Receptor Tyrosine Kinase Ligands in Acute Pancreatitis

Multicenter Prospective Cohort Study on TAM Receptor Tyrosine Kinase Ligands for Predicting the Severity of Acute Pancreatitis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07023055

Enrollment

896

Registered

2025-06-15

Start date

2024-01-01

Completion date

2025-03-01

Last updated

2025-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatic Necrosis, Acute Pancreatitis (AP)

Brief summary

AXL and MERTK are homologous members of the TAM (TYRO3, AXL, MERTK) receptor tyrosine kinase family. They function as critical regulators of antiviral immunity, autoimmune responses, and tumor microenvironment modulation through their bridging ligands, GAS6 (Growth Arrest-Specific 6) and PROS1 (Protein S). These receptors serve as damage sensors that negatively regulate inflammation, promote tissue repair/remodeling, and modulate fibrotic processes in chronic inflammatory conditions. Building upon our previous work demonstrating the pivotal role of the AXL/MERTK signaling axis in AP pathogenesis - particularly in pancreatic necrosis regulation, this clinical study seeks to evaluate the prognostic value of the TAM receptor ligands GAS6 and PROS1 as biomarkers for predicting AP severity.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

1. Age 18-80 years. 2. Patients diagnosed with acute pancreatitis in outpatient/emergency departments, inpatient wards, or health examination centers starting from 2024.

Exclusion criteria

1. Patients with chronic pancreatitis or pancreatic cancer. 2. Pregnant or lactating women. 3. Patients who did not provide informed consent. 4. Patients with severe organic diseases, such as malignant tumors, acute myocardial infarction, or large-scale cerebral infarction.

Design outcomes

Primary

Measure	Time frame	Description
Proportion of Participants with Severe Acute Pancreatitis	2 days	AP severity was classified as mild (MAP), moderately severe (MSAP), or severe (SAP) according to the revised Atlanta classification.

Secondary

Measure	Time frame	Description
Incidence Rate of Persistent Organ Failure (≥48 Hours) in Acute Pancreatitis	2 days	Organ dysfunction in acute pancreatitis refers to the impairment of one or more organ systems (e.g., respiratory, renal, cardiovascular) due to systemic inflammation, often leading to persistent organ failure (≥48 hours), a hallmark of severe acute pancreatitis (SAP).

Countries

China

Outcome results